Bicocca Open Archive

Logo unimib boa
GAMBACORTI PASSERINI, CARLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 39.225
AS - Asia 22.960
EU - Europa 17.183
SA - Sud America 3.177
AF - Africa 528
OC - Oceania 56
Continente sconosciuto - Info sul continente non disponibili 40
Totale 83.169
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 37.137
SG - Singapore 7.892
CN - Cina 4.527
VN - Vietnam 4.027
IT - Italia 3.751
HK - Hong Kong 2.950
DE - Germania 2.723
RU - Federazione Russa 2.673
BR - Brasile 2.377
IE - Irlanda 1.780
CA - Canada 1.762
SE - Svezia 1.729
UA - Ucraina 1.081
GB - Regno Unito 927
FR - Francia 746
IN - India 629
BD - Bangladesh 567
FI - Finlandia 473
KR - Corea 385
TR - Turchia 358
ID - Indonesia 332
AR - Argentina 325
IQ - Iraq 238
PL - Polonia 218
ES - Italia 185
ZA - Sudafrica 183
JP - Giappone 173
MX - Messico 173
PK - Pakistan 167
AT - Austria 166
NL - Olanda 160
DK - Danimarca 120
SA - Arabia Saudita 114
EC - Ecuador 110
BE - Belgio 107
CO - Colombia 99
VE - Venezuela 94
PH - Filippine 88
UZ - Uzbekistan 80
MA - Marocco 79
CH - Svizzera 69
CL - Cile 59
EG - Egitto 50
TN - Tunisia 48
MY - Malesia 46
AU - Australia 42
LT - Lituania 42
PE - Perù 41
KE - Kenya 39
JO - Giordania 38
CZ - Repubblica Ceca 37
BG - Bulgaria 36
AE - Emirati Arabi Uniti 32
EU - Europa 32
PY - Paraguay 32
ET - Etiopia 31
IR - Iran 31
NP - Nepal 31
TH - Thailandia 28
JM - Giamaica 27
RO - Romania 27
CR - Costa Rica 26
DO - Repubblica Dominicana 26
AZ - Azerbaigian 24
PS - Palestinian Territory 20
BO - Bolivia 19
GR - Grecia 19
KG - Kirghizistan 19
OM - Oman 19
IL - Israele 18
KZ - Kazakistan 18
LB - Libano 18
PT - Portogallo 18
UY - Uruguay 18
DZ - Algeria 16
TW - Taiwan 16
TT - Trinidad e Tobago 15
HN - Honduras 14
NO - Norvegia 14
AL - Albania 13
MU - Mauritius 13
RS - Serbia 12
NI - Nicaragua 11
NZ - Nuova Zelanda 11
SY - Repubblica araba siriana 10
AO - Angola 9
LY - Libia 9
NG - Nigeria 9
PA - Panama 9
GE - Georgia 8
GT - Guatemala 8
SK - Slovacchia (Repubblica Slovacca) 8
AM - Armenia 7
BH - Bahrain 7
EE - Estonia 7
KW - Kuwait 7
SC - Seychelles 7
CI - Costa d'Avorio 6
HR - Croazia 6
LA - Repubblica Popolare Democratica del Laos 6
Totale 83.043
Salva come PNG Salva come JPEG
Città #
Ann Arbor 6.174
Singapore 4.399
Ashburn 3.317
Hong Kong 2.878
Woodbridge 2.706
Fairfield 2.296
San Jose 1.881
Dublin 1.738
Houston 1.662
Frankfurt am Main 1.577
Chandler 1.490
Wilmington 1.323
Milan 1.320
Toronto 1.269
Ho Chi Minh City 1.186
Jacksonville 1.051
Hanoi 972
Seattle 951
New York 936
Santa Clara 803
Dearborn 794
Cambridge 784
Los Angeles 718
Beijing 643
Dallas 625
Chicago 620
Hefei 615
Princeton 564
The Dalles 528
Seoul 359
Lauterbourg 328
Nanjing 320
Shanghai 307
Moscow 275
Buffalo 252
Altamura 249
Jakarta 249
Lawrence 249
São Paulo 247
Boardman 235
Council Bluffs 218
Göttingen 188
Munich 176
Lachine 173
Helsinki 165
Da Nang 162
Guangzhou 158
San Diego 142
Haiphong 130
Orem 129
Nuremberg 126
Tokyo 126
Warsaw 124
London 122
Rome 108
Lissone 101
Vienna 101
Brussels 99
Andover 98
Nanchang 98
Shenyang 96
Montreal 95
Ottawa 93
Dong Ket 91
Chennai 88
Johannesburg 85
Rio de Janeiro 85
Baghdad 83
Fremont 81
Tianjin 78
Changsha 76
Hải Dương 74
Stockholm 74
Brooklyn 73
Denver 73
Salt Lake City 72
Tashkent 71
Atlanta 70
Biên Hòa 70
Turku 69
Hebei 68
Fürstenwalde 65
Washington 64
Dhaka 63
Kent 62
Romola 62
Poplar 60
Jinan 58
Can Tho 57
Jiaxing 57
Ninh Bình 57
Pune 57
Ha Long 56
Phoenix 56
Columbus 55
Quận Bình Thạnh 55
Lappeenranta 53
Lodz 52
Boston 51
Curitiba 51
Totale 54.390
Salva come PNG Salva come JPEG
Nome #
Single-center study on SARS-CoV-2 infection in patients affected by CML: Vaccination status and bosutinib therapy as possible protective factors for hospitalization 661
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways 606
Characterization of intra-host SARS-CoV-2 variants improves phylogenomic reconstruction and may reveal functionally convergent mutations 567
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 536
A bioinformatics procedure to identify and annotate somatic mutations in whole-exome sequencing data 520
VERSO: a comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples 514
CNS relapse risk in HIV-positive patients affected by DLBCL and HGBL – a retrospective study of the musthal cohort 486
ETNK1 mutations promote ROS production and DNA damage through increased mitochondrial activity 466
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene 461
OncoScore: A novel, Internet-based tool to assess the oncogenic potential of genes 458
Evaluating the performance of large language models in haematopoietic stem cell transplantation decision-making 454
RNA-seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients 454
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study 450
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 450
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib 445
Acute myeloid leukaemia niche regulates response to L-asparaginase 445
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma 443
ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine 437
The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis 436
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 429
Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years 426
ETNK1 mutations in atypical chronic myeloid leukemia induce a mutator phenotype that can be reverted with phosphoethanolamine 421
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub 415
ETNK1 MUTATIONS INCREASE MITOCHONDRIAL ACTIVITY AND PROMOTE DNA DAMAGE THROUGH ROS PRODUCTION 412
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 410
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions 409
VERSO: a comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples 409
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 403
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 402
WHOLE-EXOME SEQUENCING OF A PHILADELPHIA NEGATIVE CHRONIC MYELOID LEUKEMIA PATIENT THROUGH THE EXON-CAPTURE TECHNIQUE 398
A computational procedure to identify and annotate somatic mutations in next-generation sequencing data 396
Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes 394
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization 394
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 382
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 381
Idiopathic erythrocytosis: a germline disease? 378
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 378
Characterization of compound 584, an Abl kinase inhibitor with lasting effects 373
Imatinib long term effects study: three years of follow-up and assessment 373
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia 371
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 370
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells 362
BCR-ABL nuclear entrapment kills human CML cells: Ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B 360
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells 360
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia 354
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib 352
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia 345
Whole-Exome Sequencing Data - Identifying Somatic Mutations 345
Integrating mutational profiles and transcriptional data with ASTUTE to elucidate the key molecular functions involved in the pathogenesis of cancer 344
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 335
Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors 334
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation 333
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells 333
Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors 333
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036 333
Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy 331
Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients’ by leguay et al 329
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 329
Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL) 329
Chronic myeloid leukemia: Second-line drugs of choice 328
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 327
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma 325
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies 324
Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases 324
Inhibition of RET tyrosine kinase by SU5416 323
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 321
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition 320
Oncoscore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis 319
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants 318
A fatal case of TEMPI syndrome, refractory to proteasome inhibitors and autologous stem cell transplantation 318
The ALK gene, an attractive target for inhibitor development 315
Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy 313
Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex 313
Remission of low-grade lymphomatoid granulomatosis with extensive pulmonary involvement following immune restoration via antiretroviral therapy in a newly diagnosed HIV patient 312
CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data 312
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors 311
Dissection of the RET/ß-catenin interaction in the TPC1 thyroid cancer cell line 309
Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia 307
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy 307
Gene expression signature of non-involved lung tissue associated with survival in lung adenocarcinoma patients 305
Integrated Analysis of Whole-Exome Sequencing and Micrornas Expression in Blast Crisis Transformation of Chronic Myeloid Leukemia 304
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase 304
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation 301
Evidence for D276G and L364I Bcr-Abl mutations in Ph plus leukaemic cells obtained from patients resistant to Imatinib 300
ALK inhibitors for clinical use in cancer therapy 297
Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling 295
BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients 295
Reply to P. Laneuville et al 295
Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia 289
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias 289
Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors 289
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma 287
Increased sFLT-1/PlGF ratio in COVID-19: A novel link to angiotensin II-mediated endothelial dysfunction 287
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes 286
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells 285
ETNK1 is an early event and SETBP1 a late event in atypical Chronic Myeloid Leukemia 285
In Vitro and in Vivo Characterization of Bosutinib as Substrate of the Pglycoprotein Efflux Transporter 283
Hb Monza: A novel extensive HBB duplication with preserved α-β subunit interaction and unstable hemoglobin phenotype 281
Identification of a Novel Splicing Mutation in Blast Crisis Transformation of Chronic Myeloid Leukemia Integrating Whole-exome and RNA-Seq data 280
DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients 279
Totale 36.616
Salva come PNG Salva come JPEG
Categoria #
all - tutte 266.092
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 266.092
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021555 0 0 0 0 0 0 0 0 0 0 0 555
2021/20224.093 331 406 499 279 276 366 213 228 206 304 329 656
2022/20236.561 864 1.919 566 554 469 932 72 333 418 126 152 156
2023/20245.361 129 146 202 235 671 1.456 978 159 443 287 90 565
2024/202513.373 790 1.498 734 665 1.115 506 914 419 1.112 1.954 1.217 2.449
2025/202631.152 4.223 2.279 2.407 3.481 3.379 1.628 4.446 1.382 2.449 2.448 2.242 788
Totale 84.975